HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Evaxion Biotech (NASDAQ:EVAX) and maintained a price target of $14, indicating confidence in the company's future performance.
September 20, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Evaxion Biotech and maintained a $14 price target, suggesting positive expectations for the company's stock performance.
The reiteration of a Buy rating and maintenance of a $14 price target by HC Wainwright & Co. indicates strong confidence in Evaxion Biotech's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100